|
|
Avanir Pharmaceuticals,Incorporation - Comparative Business Analysis Snapshot
Business Description
Avanir Pharmaceuticals,Incorporation Formerly known as AVANIR Pharmaceuticals. The Group's principal activity is to develop, acquire and commercialize novel therapeutic products for the treatment of chronic diseases. The product candidate address therapeutic markets that include the central nervous system and inflammatory diseases. The product candidate Zenvia is in the phase III clinical development for the treatment of pseudobulbar affect and diabetic peripheral neuropathic pain. The Group also has an ongoing development program with Novartis for the treatment of inflammatory disease.
Competitor Analysis
This analysis compares Avanir Pharmaceuticals,Incorporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
